01重点学术场次Priority Sessions8 场
本专题的重点场次包含 Hot Line、LBCS、New ESC Guidelines、Ask the Trialists、Guidelines in Practice、Great Debates 等。
指南与标准1 场
Guidelines in Practice
ESC 心房颤动管理指南
ESC Guidelines for the Management of Atrial Fibrillation
房颤消融（PFA/冷冻）4 场Hot Line 1
LBCS
房颤消融的演进：能量、标测与精准患者选择
The evolution of atrial fibrillation ablation: energy, mapping and precision patient selection
混合消融对比导管消融治疗持续性房颤合并心衰：HALT AF 随机试验
Hybrid Versus Catheter Ablation for Persistent Atrial Fibrillation and Heart Failure: The HALT AF Randomised Trial
症状性持续性心房颤动患者脉冲场消融肺静脉隔离联合或不联合后壁消融的比较
Pulmonary Vein Isolation with Pulsed Field Ablation with versus without Posterior Wall Ablation in Patients with Symptomatic Persistent Atrial Fibrillation
脉冲场消融联合或不联合关键基质电图标测治疗非阵发性心房颤动：前瞻性多中心随机研究（PEAK-AF 研究）
Pulsed-Field Ablation With/Without Electrogram Mapping of Key Substrates for Non-paroxysmal Atrial Fibrillation: A Prospective Multicenter Randomized Study (PEAK-AF Study)
双能量局灶脉冲电场消融系统治疗阵发性房颤的 12 个月安全性与有效性：FlexPulse IDE 研究结果
12-month safety and effectiveness of a dual energy focal pulsed field ablation system to treat paroxysmal atrial fibrillation: results from the FlexPulse IDE study
AI 引导共享决策优化房颤导管消融患者选择：AI-PAFA 随机临床试验
AI-Guided Shared Decision-Making for Optimizing Patient Selection in Atrial Fibrillation Catheter Ablation: A Randomized Clinical Trial (AI-PAFA Trial)
LBCS
晚期临床试验：优化房颤消融
Late-Breaking Clinical Trials: optimising atrial fibrillation ablation
房颤消融中改善食管保护：多中心随机对照试验
Improving esophageal protection during AF ablation: a multicenter randomized controlled trial
药物复律无效的持续性房颤患者在肺静脉隔离基础上加行左房后壁隔离：LEAP-AF 随机临床试验
Left atrial posterior isolation in addition to pulmonary vein isolation in patients with persistent AF refractory to pharmacologic cardioversion: The LEAP-AF randomized clinical trial
持续性房颤患者房颤心律下行附加低电压区消融：一项前瞻性随机临床试验
Additional Low-Voltage-Area ablation During Atrial Fibrillation Rhythm In Patients With Persistent Atrial Fibrillation: a prospective, randomized clinical trial
房速中 Ripple 标测引导峡部消融对比局部激动时间引导消融的随机对照试验：Ripple AT-plus 研究
A Randomised Controlled Trial of Ripple Mapping-guided isthmus ablation versus Local Activation Time-guided ablation in Atrial Tachycardia: The Ripple AT-plus study
持续性房颤患者中以求终止房颤为手术终点消融对比预设消融策略后复律的随机对照研究
A Randomized Controlled Study of Ablation Pursuing Atrial Fibrillation Termination as a Procedural Endpoint versus Prespecified Ablation Strategy Followed by Cardioversion in Patients with Persistent
FLEX-PVI 试验：使用柔性头端接触力感应导管进行高功率短时程肺静脉隔离
The FLEX-PVI Trial: High-Power Short-Duration Pulmonary Vein Isolation Using a Flexible-Tip Contact Force-Sensing Catheter
Hot Line
HOT LINE 8（全球首发专场）
HOT LINE 8
AFFIRMO：衰弱、多重共病与多重用药老年人的房颤综合管理
AFFIRMO - Atrial Fibrillation integrated approach in FraIl, multimoRbid and polyMedicated Older people
PVI-SHAM-AF：房颤中肺静脉隔离对比假手术
PVI-SHAM-AF: Pulmonary Vein Isolation versus SHAM in AF
NEXAF——非永久性房颤患者的长期运动
NEXAF - Long-term exercise in patients with non-permanent atrial fibrillation
IDEAL-AF：持续性房颤的个体化低电压区消融
IDEAL-AF: Individualised Low Voltage Ablation in Persistent AF
Great Debates
焦点辩论：房颤患者不用口服抗凝——未来愿景还是危险幻想
Great Debates: atrial fibrillation without oral anticoagulation - future vision or dangerous illusion?
房颤消融成功后能否停用口服抗凝药
Can we stop oral anticoagulation after successful atrial fibrillation ablation?
正方Boyoung JoungYonsei University反方Isabelle C Van GelderUniversity Medical Centre Groningen评论员Jeff HealeyPopulation Health Research Institute
左心耳封堵正在取代口服抗凝吗
Is left atrial appendage closure replacing oral anticoagulation?
正方Devi NairSt. Bernards Medical Centre反方Paulus KirchhofUniversity Heart and Vascular Centre Hamburg (UHZ)评论员Madelene Carina Blomstrom-LundqvistOrebro University Hospital
生理性起搏与传导系统1 场
Great Debates
焦点辩论：心脏植入式电子器械治疗的新面孔
Great Debates: the new kids on the block in cardiac implantable electronic device therapy
传导系统起搏 vs 无导线起搏治疗心动过缓
Conduction system pacing vs. leadless pacing for treating bradycardia
正方Haran BurriUniversity hospitals of Geneva反方Clemens SteinwenderKepler University Hospital Linz评论员Sana Al-KhatibDuke University Medical Center
经静脉 vs 非经静脉植入式心律转复除颤器
Transvenous vs. non-transvenous implantable cardioverter defibrillators
正方Carsten W IsraelBethel-Clinic反方Jens Cosedis NielsenAarhus University Hospital评论员Jacqueline JozaMcGill University Health Centre
左心耳封堵1 场
LBCS
卒中预防进展：抗凝、抗血小板与左心耳封堵
Advances in stroke prevention: anticoagulation, antiplatelet therapy and left atrial appendage closure
半剂量抗凝对比标准抗血小板治疗预防左心耳封堵后无症状脑栓塞：HALO-SCE 随机试验
Half-Dose Anticoagulation versus Standard Antiplatelet Therapy for Preventing Silent Cerebral Embolism After Left Atrial Appendage Occlusion: The HALO-SCE Randomized Trial
OCEANIC-STROKE 随机化后前 90 天双联抗血小板治疗：受试者特征及与 asundexian 的交互作用
Dual antiplatelet therapy (DAPT) during the first 90 days post-randomisation in OCEANIC-STROKE: participant characteristics and interaction with asundexian
左心耳封堵与药物治疗的性别特异性结局：CLOSURE-AF-DZHK-16 试验
Sex-Specific Outcomes of Left Atrial Appendage Closure Versus Medical Therapy: The CLOSURE-AF-DZHK-16 Trial
低出血风险房颤患者中左心耳封堵作为 NOAC 替代用于卒中预防：患者层面荟萃分析
Left Atrial Appendage Closure as an Alternative to NOAC for Stroke Prevention in Patients with Atrial Fibrillation at Low Bleeding Risk: A Patient-Level Meta-Analysis
植入式监测与房颤筛查1 场
LBCS
晚期临床试验：房颤检测到治疗策略
Late-Breaking Clinical Trials: atrial fibrillation detection to treatment strategies
永久性房颤合并心衰症状患者中长期预后：小剂量地高辛对比 β 受体阻滞剂
Longer-term prognostic benefit of low-dose digoxin versus beta-blockers in patients with permanent atrial fibrillation and symptoms of heart failure
老年持续性房颤患者：消融对比起搏
Ablate versus Pace in Elderly Patients With Persistent Atrial Fibrillation
CANDLE-AF：不明原因卒中后无创单导联心电图监测策略检测房颤的效果比较
CANDLE-AF: Comparative effectiveness of noninvasive single-lead ECG monitoring strategies for atrial fibrillation detection after cryptogenic stroke
REAL-PATCH-AF：老年人房颤筛查中自用心电图贴片系统的真实世界表现：六种系统的随机比较
REAL-PATCH-AF: Real-world performance of self-applied ECG patch systems for atrial fibrillation screening in older adults: a randomized comparison of six systems
02中国专家参与场次China Faculty3 场
| 中国专家参与的报告 |
|---|
| 房颤消融（PFA/冷冻） · 3 项中国专家报告 |
脉冲场消融联合或不联合关键基质电图标测治疗非阵发性心房颤动：前瞻性多中心随机研究（PEAK-AF 研究） Pulsed-Field Ablation With/Without Electrogram Mapping of Key Substrates for Non-paroxysmal Atrial Fibrillation: A Prospective Multicenter Randomized Study (PEAK-AF Study) |
持续性房颤患者房颤心律下行附加低电压区消融：一项前瞻性随机临床试验 Additional Low-Voltage-Area ablation During Atrial Fibrillation Rhythm In Patients With Persistent Atrial Fibrillation: a prospective, randomized clinical trial |
持续性房颤患者中以求终止房颤为手术终点消融对比预设消融策略后复律的随机对照研究 A Randomized Controlled Study of Ablation Pursuing Atrial Fibrillation Termination as a Procedural Endpoint versus Prespecified Ablation Strategy Followed by Cardioversion in Patients with Persistent |
| 左心耳封堵 · 1 项中国专家报告 |
半剂量抗凝对比标准抗血小板治疗预防左心耳封堵后无症状脑栓塞：HALO-SCE 随机试验 Half-Dose Anticoagulation versus Standard Antiplatelet Therapy for Preventing Silent Cerebral Embolism After Left Atrial Appendage Occlusion: The HALO-SCE Randomized Trial |
03本领域中国研究China Abstracts40 篇
| 研究标题 | 第一作者 | 所在机构 |
|---|---|---|
| 口服抗凝 · 6 篇 | ||
房颤患者既往口服抗凝药使用及转换为依度沙班的临床结局：ETNA-AF中国研究2年随访数据 Clinical outcomes by prior OAC use and switching to edoxaban in atrial fibrillation: 2-year follow-up data from the ETNA-AF China study | Chang-Sheng Ma | 北京安贞医院 |
中国房颤患者接受依度沙班治疗2年随访主要出血事件的预测因素 Predictors of major bleeding events among Chinese patients receiving edoxaban for atrial fibrillation at 2-year follow-up | Chang-Sheng Ma | 北京安贞医院 |
左心耳封堵对比口服抗凝治疗衰弱房颤患者：真实世界研究 Left atrial appendage occlusion versus oral anticoagulation in frail patients with atrial fibrillation: a real-world study | Tong Liu | 天津医科大学第二医院 |
CHA2DS2-VASc、CHA2DS2-VASc-60与CHA2DS2-VA评分对房颤卒中风险分层的比较：ETNA-AF中国研究的启示 Comparison of CHA2DS2-VASc, CHA2DS2-VASc-60 and CHA2DS2-VA score for stroke risk stratification in patients with atrial fibrillation: insights from the ETNA-AF-China study | Chang-Sheng Ma | 北京安贞医院 |
DOAC治疗期间肾功能恶化房颤患者的抗凝策略与临床结局 Anticoagulation strategies and clinical outcomes in atrial fibrillation patients developing renal deterioration during DOAC therapy | Tze-Fan Chao | 台北荣民总医院 |
既往颅内出血的非瓣膜性房颤患者抗凝治疗恢复时机 Timing of anticoagulation therapy resumption among non-valvular atrial fibrillation (NVAF) patients with prior intracranial haemorrhage | Wen Sun | 香港中文大学 |
| 预防 · 4 篇 | ||
健康生活方式与房颤遗传易感性的关系：国家前瞻性队列结果 Relation of healthy lifestyle to the genetic predisposition for atrial fibrillation: results from a national prospective cohort | Rongfeng Zhang | 大连医科大学附属第一医院 |
生物学衰老加速与房颤患者不良心血管预后的关联：多中心真实世界队列研究 Association between biological aging acceleration and adverse cardiovascular prognosis in atrial fibrillation patients: a multicenter real-world cohort study | Tong Liu | 天津医科大学第二医院 |
药物与非药物干预预防心脏手术后房颤：系统评价与网络荟萃分析 Pharmacologic and non-pharmacologic interventions for preventing postoperative atrial fibrillation in cardiac surgery: systematic review and network meta-analysis | Chenyu Liu | 中国医学科学院北京协和医学院阜外医院 |
经导管主动脉瓣置换术后永久起搏器植入风险分层模型的开发 Development of a risk stratification model for permanent pacemaker implantation after Transcatheter Aortic Valve Replacement (TAVR) | Tong Liu | 天津医科大学第二医院 |
| 房颤相关卒中 · 2 篇 | ||
CHADS₂、CHA₂DS₂-VASc、CHA₂DS₂-VA、HAS-BLED与HELT-E₂S₂评分在依度沙班治疗房颤患者中的头对头比较：ETNA-AF全球项目2年分析 Head-to-head comparison of CHADS₂, CHA₂DS₂-VASc, CHA₂DS₂-VA, HAS-BLED, and HELT-E₂S₂ scores in edoxaban treated atrial fibrillation patients: a 2-year analysis from the ETNA-AF Global program | Chun-Chieh Wang | 台北长庚纪念医院 |
55至64岁筛查检出与临床诊断的未达抗凝标准房颤患者卒中风险增加 Increased risk of stroke in young (aged 55 to 64) screen-detected and clinically diagnosed atrial fibrillation patients who do not meet criteria for oral anticoagulation therapy at time of diagnosis: | Wen Sun | 香港中文大学 |
| 房颤患病率与发病率 · 2 篇 | ||
年龄修饰植物性饮食指数与心房颤动的关联：英国生物样本库前瞻性队列研究 Age as an effect modifier of the association between plant-based diet index and atrial fibrillation: a prospective cohort study from the UK Biobank population | Huihui Bao | 南昌大学第二附属医院 |
收缩压达标时间与新发心房颤动的关联：英国生物样本库前瞻性队列研究 Association between systolic blood pressure time in target range and incident atrial fibrillation: a prospective cohort study in the UK Biobank | Huihui Bao | 南昌大学第二附属医院 |
| 室性心律失常消融 · 2 篇 | ||
单极局部激动时间优于双极电图定位流出道室性早搏 Unipolar local activation time outperforms bipolar electrograms for localizing outflow tract premature ventricular contractions | Li Shu | 浙江大学医学院附属第二医院 |
单极与双极放电模式脉冲电场消融在心室中比较的疗效与安全性 Comparative efficacy and safety of pulse field ablation using monopolar versus bipolar discharge mode in ventricles | Zhenhao Zhang | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
| 心脏再同步化治疗 · 2 篇 | ||
经左膈下静脉入路经静脉膈肌起搏的可行性：试点研究 Feasibility of transvenous diaphragm pacing via left inferior phrenic vein: a pilot study | Tianbao Yao | 上海交通大学医学院附属仁济医院 |
左房最小容积指数预测心脏再同步治疗后持久逆向重构 Left atrial minimum volume index predicts durable reverse remodeling following cardiac resynchronisation therapy | Di Zhou | 中国医学科学院北京协和医学院阜外医院 |
| 冠心病 · 2 篇 | ||
冠心病血运重建术后个体化风险教育的AI副驾驶 AI copilot of personalized risk education for post-revascularization care in patients with coronary artery disease (CAD) | Huizi Yu | 威尔斯亲王医院 |
电负性HDL重构独立关联造影阻塞性冠心病 Electronegative HDL remodeling is independently associated with angiographic obstructive coronary artery disease | Yen-Tuan Huang | 台中荣民总医院 |
| 左心耳封堵 · 2 篇 | ||
左心耳电隔离减少持续性房颤患者器械封堵术后残余开放 Left atrial appendage electrical isolation reduces residual patency after device closure in persistent atrial fibrillation patients | Jian Sun | 上海交通大学医学院附属新华医院 |
左心耳封堵与口服抗凝药物治疗房颤的比较：系统评价与荟萃分析的最新证据 Left atrial appendage closure versus oral anticoagulants in atrial fibrillation: updated evidence from a systematic review and meta-analysis | Chen Wang | 浙江大学医学院附属第二医院 |
| 临床 · 2 篇 | ||
整合管理改善多病共存房颤患者结局：MIRACLE-AF试验的启示 Integrated care improves outcomes in multimorbid patients with atrial fibrillation: insights from the MIRACLE-AF trial | Ming Fang Li | 南京医科大学第一附属医院 |
不同肾功能估算公式对直接口服抗凝药治疗房颤患者不良结局的预测 Predictions of adverse outcomes using different renal function estimation formulas in patients with atrial fibrillation receiving direct oral anticoagulants | Tze-Fan Chao | 台北荣民总医院 |
| 特发性扩张型心肌病 · 1 篇 | ||
心脏磁共振整合血浆蛋白质组学用于特发性扩张型心肌病的表型分析与风险分层 Integrated cardiac magnetic resonance and plasma proteomics for phenotyping and risk stratification in idiopathic dilated cardiomyopathy | Anhu Wu | 北京协和医院 |
| 房颤分型 · 1 篇 | ||
非靶向代谢组学鉴定跨人群房颤心房纤维化与复发的关键代谢物 Untargeted-metabolomics identifies key metabolites for atrial fibrosis and recurrence of atrial fibrillation indication across populations | Ming Chu | 江苏省人民医院 |
| 节律控制与房颤外科 · 1 篇 | ||
心脏磁共振评估脉冲电场消融所致室间隔损伤：猪模型的病理与功能结局相关性 Cardiac magnetic resonance for assessment of pulsed field ablation-induced ventricular septal lesions: correlation with pathology and functional outcomes in a porcine model | Qingxing Chen | 复旦大学附属中山医院 |
| 患者认知功能与自主能力 · 1 篇 | ||
基于ABC路径整合管理的基线认知功能与房颤患者临床结局：MIRACLE-AF试验的启示 Baseline cognitive function and clinical outcomes with integrated care management based on the ABC pathway in patients with atrial fibrillation: insights from MIRACLE-AF Trial | Ming Fang Li | 南京医科大学第一附属医院 |
| 节律控制与导管消融 · 1 篇 | ||
导管消融与起搏器植入治疗心房颤动合并病态窦房结综合征的远期临床结局：多中心真实世界队列研究 Long-term clinical outcomes of catheter ablation versus pacemaker implantation in patients with atrial fibrillation and sick sinus syndrome: a multicenter real-world cohort study | Xinyi Yang | 天津医科大学第二医院 |
| 疾病建模 · 1 篇 | ||
肠道菌群衍生异戊酸通过抑制GSDME依赖性焦亡缓解心房颤动 Gut microbiota-derived isovaleric acid alleviates atrial fibrillation by suppressing GSDME-dependent pyroptosis | Ning Ding | 西安交通大学第一附属医院 |
| 肥厚型心肌病 · 1 篇 | ||
中国肥厚型心肌病患儿心脏性猝死机器学习预测模型的构建与验证：多中心回顾性研究 Construction and validation of a machine learning-based prediction model for sudden cardiac death in chinese children with hypertrophic cardiomyopathy: a multicenter retrospective study | Bo Han | 山东省立医院 |
| 房颤合并心衰 · 1 篇 | ||
右房与左房应变及几何参数在预测阵发性房颤消融结局中的差异 Differences between right and left atrial strain and geometric parameters in prediction of ablation outcomes for paroxysmal atrial fibrillation | Songyun Chu | 北京大学第一医院 |
| 起搏器治疗 · 1 篇 | ||
新型起搏器电图形态监测算法在传导系统起搏中的评估 Evaluation of a novel pacemaker-based electrogram morphology monitor algorithm in conduction system pacing | Weiwei Zhang | 上海市胸科医院 |
| 心律失常的细胞机制 · 1 篇 | ||
整合单细胞测序与空间转录组学解析心房颤动肺静脉袖的细胞景观 Landscape of pulmonary vein sleeves during atrial fibrillation by integrating single-cell sequencing and spatial transcriptomics | Yaping Wang | 浙江大学医学院附属第二医院 |
| 致心律失常性右心室心肌病 · 1 篇 | ||
FAP靶向CAR巨噬细胞治疗改善Dsg2突变致心律失常性心肌病小鼠的心功能并减少纤维化 Fap-directed CAR macrophage therapy improves cardiac function and reduces fibrosis in Dsg2-mutant arrhythmogenic cardiomyopathy mice | Yiqi Zhao | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
| 流行病学、预后与结局 · 1 篇 | ||
特发性左束支传导阻滞结局与通路的系统分析 Systematic analysis of outcomes and pathways related to idiopathic left bundle branch block | Rongfeng Zhang | 大连医科大学附属第一医院 |
| 心衰与心肌病机制 · 1 篇 | ||
心外膜脂肪组织预测射血分数保留型心力衰竭患者早期心房颤动 Epicardial adipose tissue predicts early-stage atrial fibrillation in heart failure with preserved ejection fraction | Shu-Fan Deng | 台湾大学附属医院 |
| 心室率控制 · 1 篇 | ||
房颤合并心力衰竭患者左束支区域起搏与房室结消融治疗应答的预测因素 Predictors of therapeutic response to left bundle branch area pacing and atrioventricular node ablation in patients with atrial fibrillation and heart failure | Shen Lishui | 同济大学附属上海市第十人民医院 |
| 心电图 · 1 篇 | ||
TAVR术后左束支传导阻滞患者Notch时间标准的验证 Validation of the 'Time to Notch' criterion in patients with left bundle branch block following transcatheter aortic valve replacement | Tong Liu | 天津医科大学第二医院 |
| 激发试验与自主神经评估 · 1 篇 | ||
基于RRI的机器学习系统用于难治性血管迷走性晕厥的预警与紧急警报 RRI-based machine learning system for early warning and emergency alerts of refractory vasovagal syncope | Xiaoyun Yang | 同济医院-同济医学院 |
04企业卫星会Industry Symposia25 个系列
赞助商分布14 场 · Medtronic 4 场 · Abbott 4 场 · Bristol Myers Squibb and Johnson & Johnson Alliance 2 场 · Philips & Imricor 2 场 · Boston Scientific 2 场 · Bayer AG 2 场 · Daiichi Sankyo Europe GmbH 1 场 · Regeneron 1 场 · Philips 1 场 · Novartis
指南与标准1 个系列
Boston Scientific
房颤卒中预防：2024 指南之外的新证据
Avoiding stroke in atrial fibrillation: evolving evidence beyond the 2024 Guidelines
欢迎与介绍
Welcome & introduction
2026 年卒中预防：不断演变的格局
Stroke prevention in 2026: an evolving landscape
当前卒中预防：仍存的挑战
Current stroke prevention: remaining challenges
专家讨论
Panel discussion
2024 年指南以来的新证据
New evidence since the 2024 Guidelines
专家讨论
Panel discussion
… 另 2 项讲题
生理性起搏与传导系统4 个系列
Medtronic
心律管理、肾动脉消融与冠脉生理学的最新进展（系列共 3 场）
Latest innovations in cardiac rhythm management, renal denervation and coronary physiology
心律管理、肾去神经与冠脉生理学的最新创新
Latest innovations in cardiac rhythm management, renal denervation and coronary physiology
Medtronic
左束支区域起搏植入：器械、技术与陷阱
Left bundle branch area pacing implantation: tools, technique, and pitfalls
左束支区域起搏植入：工具、技术与陷阱
Left bundle branch area pacing implantation: tools, technique, and pitfalls
Medtronic
患者选择：无导线起搏还是传导系统起搏
Patient selection: when to choose leadless vs conduction system pacing
患者选择：何时选择无导线对比传导系统起搏
Patient selection: when to choose leadless vs conduction system pacing
Medtronic
无导线起搏、传导系统起搏与冠脉生理学的最新进展
Latest innovations in leadless and conduction system pacing, and coronary physiology
无导线与传导系统起搏及冠脉生理学的最新创新
Latest innovations in leadless and conduction system pacing, and coronary physiology
植入式监测与房颤筛查3 个系列
Medtronic
血管外植入式心律转复除颤器：植入流程、程控与随访（系列共 3 场）
Extravascular implantable cardioverter-defibrillator: implant procedure, programming and follow-up
血管外植入式心律转复除颤器：植入流程、程控与随访
Extravascular implantable cardioverter-defibrillator: implant procedure, programming and follow-up
Philips
电极与瓣膜：三尖瓣介入前的 CIED 管理
Leads and valves — Managing cardiac implantable electronic devices before tricuspid intervention
导线与瓣膜——三尖瓣介入前的植入式心脏电子器械管理
Leads and valves — Managing cardiac implantable electronic devices before tricuspid intervention
Medtronic
无腔 ICD 电极技术：OmniaSecure 电极最新临床数据
Lumenless technology on implantable cardioverter-defibrillator leads - Latest clinical data on OmniaSecure™ lead
ICD 导线的无腔技术——OmniaSecure™ 导线最新临床数据
Lumenless technology on implantable cardioverter-defibrillator leads - Latest clinical data on OmniaSecure™ lead
房颤消融（PFA/冷冻）2 个系列
Medtronic
房颤照护的下一个时代：从植入式心电监测到先进消融技术
The next era of atrial fibrillation care: from insertable cardiac monitoring insights to advanced ablation technologies
高敏缺血性心肌病监测如何揭示真实房颤负荷、优化医疗资源利用与患者结局
How high-sensitivity ischemic cardiomyopathy monitoring reveals true atrial fibrillation burden, optimising healthcare utilisation and patient outcomes
当代消融选择：重塑房颤管理
Contemporary ablation options: reshaping atrial fibrillation management
圆桌讨论
Roundtable discussion
Boston Scientific
脉冲场消融优化房颤患者结局：时机与能量来源
Optimising atrial fibrillation patient outcomes with pulsed field ablation: timing and energy source
引言
Introduction
我的房颤患者首选什么：抗心律失常药物还是导管消融？
What is the first option for my atrial fibrillation patient: anti-arrhythmic drugs or catheter ablation?
脉冲电场消融如何取代热能消融治疗房颤
How pulsed field ablation could replace thermal energies for atrial fibrillation ablation
问答讨论
Q&A discussion
综合与其他15 个系列
Medtronic
血流动力学起搏：超越传统起搏优化心功能
Haemodynamic pacing: optimising cardiac performance beyond conventional pacing
血流动力学起搏：超越常规起搏优化心脏性能
Hemodynamic pacing: optimising cardiac performance beyond conventional pacing
Abbott
以病例为切入：远程肺动脉压力监测的临床落地（系列共 2 场）
Case based implementation of remote pulmonary artery pressure monitoring in clinical practice
远程肺动脉压监测的临床实践病例实施
Case based implementation of remote pulmonary artery pressure monitoring in clinical practice
Regeneron
卒中预防抗栓治疗的演进：XI 因子抑制是未来吗
Evolution of antithrombotic therapy for stroke prevention: is factor XI inhibition the future?
欢迎与介绍
Welcome and introduction
当前卒中预防的挑战
Current challenges in stroke prevention
应对抗栓治疗的复杂性
Navigating complexities in antithrombotic therapy
临床试验中的 XI 因子抑制
Factor XI inhibition in clinical trials
卒中预防抗栓治疗的演进：XI 因子抑制是未来吗？——问答
Evolution of antithrombotic therapy for stroke prevention: is factor XI inhibition the future? - Q&A
Bristol Myers Squibb and Johnson & Johnson Alliance
卒中预防的必要性论证（系列共 4 场）
Making the case for stroke prevention
为卒中预防立论
Making the case for stroke prevention
Philips & Imricor
心脏电生理介入磁共振（系列共 2 场）
Interventional magnetic resonance for cardiac electrophysiology
心脏电生理的介入磁共振
Interventional magnetic resonance for cardiac electrophysiology
Novartis
XI 因子抑制：房颤管理的新范式
Factor XI inhibition–a new paradigm in atrial fibrillation management
欢迎与介绍
Welcome and introduction
房颤卒中预防中未满足的医疗需求
Unmet medical need in stroke prevention in atrial fibrillation
超越直接口服抗凝药：为何我们需要血栓与出血之间的新平衡
Beyond direct oral anticoagulants: why we need a new balance between thrombosis and bleeding
新兴抗栓疗法（含 XI 因子抑制）：潜在治疗定位与目标患者人群
Emerging antithrombotic therapies, including Factor XI inhibition: potential place in therapy and patient populations of interest
专家讨论与问答
Panel discussion and Q&A
Bayer AG
构建更安全的二级卒中预防抗栓策略
Engineering safer antithrombotic strategies for secondary stroke prevention
欢迎与介绍
Welcome and introduction
设定背景：卒中后的残余风险问题
Setting the stage: the residual risk problem after stroke
聚焦证据：OCEANIC-STROKE 及其带来的改变
Evidence in focus: OCEANIC-STROKE and what it changes
设计更安全的卒中二级预防抗栓策略——专家问答
Engineering safer antithrombotic strategies for secondary stroke prevention - Q&A with the experts
Abbott
远程监测为心衰患者带来实质改变（系列共 2 场）
Making an impact with remote monitoring for heart failure patients
用心衰患者远程监测创造影响
Making an impact with remote monitoring for heart failure patients
Medtronic
无导线起搏的术式演进与流程优化
Leadless pacing procedural evolution and workflow optimisation
无导线起搏的手术演变与流程优化
Leadless pacing procedural evolution and workflow optimisation
Bayer AG
挑战固有认知：HFrEF 治疗药物为何需要再加一种
Challenging perceptions: why add more to your HFrEF medication toolkit?
聚焦可溶性鸟苷酸环化酶刺激
Spotlight on soluble guanylate cyclase stimulation
心血管死亡：终极终点
Cardiovascular mortality: the ultimate endpoint
重新思考心力衰竭恶化终点
Rethinking worsening heart failure endpoints
强化 HFrEF 药物治疗工具箱的实践应用
The enhanced HFrEF medication toolkit in practice
挑战认知：为何要在 HFrEF 药物工具箱中增加更多？——讨论与问答
Challenging perceptions: why add more to your HFrEF medication toolkit? - discussion and Q&A
最终思考
Final reflection
Daiichi Sankyo Europe GmbH
口服抗凝大辩论：起始如何选药、何时换药
Great debate on oral anticoagulation: choosing the right treatment at initiation and knowing when to switch
为什么这仍然重要
Why this still matters
DOAC 大辩论：起始并维持对比适时换药
Great direct-acting oral anticoagulants debate: start and stay vs time to switch
投票
Voting
病例聚焦：房颤与活动性恶性肿瘤
Case spotlight: atrial fibrillation and active malignancy
病例聚焦：房颤与慢性肾脏病
Case spotlight: atrial fibrillation and chronic kidney disease
从指南到灰色地带：口服抗凝的实践问题
From guidelines to grey areas: practical questions in oral anticoagulation
… 另 1 项讲题
Daiichi Sankyo Europe GmbH
心房颤动：实用综合管理策略
Atrial fibrillation: a practical comprehensive approach
房颤：实用综合管理路径
Atrial fibrillation: a practical comprehensive approach
Medtronic
心律管理的下一个时代：2026 年有什么新进展
The next era of cardiac rhythm management: what is new in 2026?
欢迎与介绍
Welcome and introduction
超越心律失常检测：植入式心脏监测的临床与经济意义
Beyond arrhythmia detection: clinical and economic implications of insertable cardiac monitoring
无导线起搏器之路进展到哪一步了？
Where are we in the leadless pacemaker journey?
血管外植入式心律转复除颤器：从试验证据到真实世界与单中心经验
Extravascular implantable cardioverter-defibrillator: from trial evidence to real-world and single-center experience
心脏节律管理的新时代：2026 年有何新进展？——结论
The next era of cardiac rhythm management: what is new in 2026? - Conclusions
Eli Lilly and Company
肠促胰素类治疗的心血管实践：理解心血管代谢风险连续谱
Incretin-based therapies in cardiovascular practice: understanding the cardiometabolic risk continuum
引言
Introduction
第 1 部分：心血管-肾脏-代谢框架与指南启示
Part 1: the cardiovascular-kidney-metabolic framework and guideline implications
第 2 部分：心血管机制与心血管代谢风险
Part 2: cardiovascular mechanisms and cardiometabolic risk
问答与闭幕致辞：从框架到实践
Q/A and closing remarks: from framework to practice
AcademicCME
房颤卒中预防会迎来新范式吗：哪些患者更适合 FXIa 抑制剂而非 DOAC
Will we see a new paradigm for stroke prevention in atrial fibrillation? Which patients are more likely to benefit from FXIa inhibition vs DOACs?
病例介绍
Introduction to cases
FXI/XIa 假说与进行中的 SPAF 试验
FXI/XIa hypothesis and ongoing SPAF Trials
实践考量
Practical considerations
病例解析与实用指南
Case resolution and practical guides
讨论/问答
Discussion/ Questions and Answers
企业卫星会内容由赞助方支持，此处仅作学术日程信息陈列，不代表编辑立场。